Acute Myeloid Leukemia, Immunotherapies and Future Directions

Acute Myeloid Leukemia (AML) is a form of blood and bone marrow cancer characterized by the rapid proliferation of abnormal white blood cells. These abnormal cells can displace normal blood cells, resulting in symptoms such as anemia and compromised immune function. AML can also metastasize via the bloodstream from the bone marrow to other body areas. Immunotherapy, a promising approach to cancer treatment, has demonstrated potential in managing AML by strengthening the immune system's capacity to identify and eradicate cancerous cells. Specifically, immunotherapy seeks to enhance the ability of T cells to recognize and attack cancer antigens while also fortifying the long-term memory and cancer-fighting capabilities of NK cells. This strategy can effectively modify NK cells, equipping them with enhanced capabilities like T cells and improving their ability to combat cancer. The ongoing immunotherapy trials have demonstrated knowledge about AML, which can be used to develop more innovative resources.